Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 Shares of Stock

Advaxis, Inc. (NASDAQ:ADXS) CFO Sara Bonstein sold 12,734 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,621.46. Following the transaction, the chief financial officer now owns 244,504 shares in the company, valued at approximately $779,967.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Advaxis, Inc. (NASDAQ:ADXS) traded up $0.12 during trading on Friday, reaching $3.30. 424,530 shares of the company were exchanged, compared to its average volume of 912,459.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The company had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.43 million. equities analysts forecast that Advaxis, Inc. will post -2.21 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 Shares of Stock” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/11/03/advaxis-inc-adxs-cfo-sara-bonstein-sells-12734-shares-of-stock.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Voya Investment Management LLC raised its position in Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 2,975 shares during the period. Cutler Capital Management LLC bought a new position in Advaxis in the second quarter worth approximately $130,000. Northern Capital Management LLC raised its position in Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 2,650 shares during the period. Stonebridge Capital Management Inc. bought a new position in Advaxis in the second quarter worth approximately $146,000. Finally, PNC Financial Services Group Inc. raised its position in Advaxis by 18.2% in the second quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 4,000 shares during the period. Institutional investors and hedge funds own 48.02% of the company’s stock.

A number of research analysts recently weighed in on ADXS shares. Cantor Fitzgerald restated a “buy” rating and set a $19.00 price objective on shares of Advaxis in a research report on Monday, September 25th. HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research report on Friday, September 15th. BidaskClub upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. Finally, ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

What are top analysts saying about Advaxis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Advaxis Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit